BACKGROUND: Maternal smoking during pregnancy has been often implicated in the development of childhood leukemia with ambiguous results. Hence, we conducted a meta-analysis aiming to summarize current evidence and quantify any tentative impact. PROCEDURE: We retrieved one cohort (553 leukemias compared to 1,440,542 children), 20 case-control studies and also analyzed the updated Greek case-control dataset with unpublished data, yielding in total 11,092 cases and 25,221 controls. RESULTS: Odds ratios reported in the studies included ranged from 0.70 to 2.20 for acute lymphocytic (ALL) and from 0.60 to 2.17 for acute myelocytic leukemia (AML). The combined effect regarding the association of maternal smoking (any vs. no) and leukemia risk was 1.03 for ALL (95% CI = 0.95-1.12, random effects model) and 0.99 for AML (95% CI = 0.90-1.09, fixed effects model). The results remained unchanged when sensitivity analyses were undertaken of studies reporting same maternal smoking periods, those focusing only on childhood leukemia deaths or investigations which did not clearly define AML subtype. CONCLUSIONS: The findings of the meta-analysis challenge the limits of traditional epidemiology to provide sound inferences when point estimates of constituent studies range around the null. In particular, this study provides no support to a hypothesis linking maternal smoking during pregnancy with subsequent development of main childhood leukemia subtypes. Further investigations employing molecular and genetic epidemiology, however, might be needed in the hope to reveal even minimal risks pertaining individuals with specific susceptibility to tobacco compounds who sustain high environmental exposures prenatally or postnatally.
BACKGROUND: Maternal smoking during pregnancy has been often implicated in the development of childhood leukemia with ambiguous results. Hence, we conducted a meta-analysis aiming to summarize current evidence and quantify any tentative impact. PROCEDURE: We retrieved one cohort (553 leukemias compared to 1,440,542 children), 20 case-control studies and also analyzed the updated Greek case-control dataset with unpublished data, yielding in total 11,092 cases and 25,221 controls. RESULTS: Odds ratios reported in the studies included ranged from 0.70 to 2.20 for acute lymphocytic (ALL) and from 0.60 to 2.17 for acute myelocytic leukemia (AML). The combined effect regarding the association of maternal smoking (any vs. no) and leukemia risk was 1.03 for ALL (95% CI = 0.95-1.12, random effects model) and 0.99 for AML (95% CI = 0.90-1.09, fixed effects model). The results remained unchanged when sensitivity analyses were undertaken of studies reporting same maternal smoking periods, those focusing only on childhood leukemia deaths or investigations which did not clearly define AML subtype. CONCLUSIONS: The findings of the meta-analysis challenge the limits of traditional epidemiology to provide sound inferences when point estimates of constituent studies range around the null. In particular, this study provides no support to a hypothesis linking maternal smoking during pregnancy with subsequent development of main childhood leukemia subtypes. Further investigations employing molecular and genetic epidemiology, however, might be needed in the hope to reveal even minimal risks pertaining individuals with specific susceptibility to tobacco compounds who sustain high environmental exposures prenatally or postnatally.
Authors: Mohammed Azab; Omar F Khabour; Karem H Alzoubi; Mays M Anabtawi; Maram Quttina; Yousuf Khader; Thomas Eissenberg Journal: Nicotine Tob Res Date: 2012-05-09 Impact factor: 4.244
Authors: Catherine Metayer; Eleni Petridou; Juan Manuel Mejía Aranguré; Eve Roman; Joachim Schüz; Corrado Magnani; Ana Maria Mora; Beth A Mueller; Maria S Pombo de Oliveira; John D Dockerty; Kathryn McCauley; Tracy Lightfoot; Emmanouel Hatzipantelis; Jérémie Rudant; Janet Flores-Lujano; Peter Kaatsch; Lucia Miligi; Catharina Wesseling; David R Doody; Maria Moschovi; Laurent Orsi; Stefano Mattioli; Steve Selvin; Alice Y Kang; Jacqueline Clavel Journal: Am J Epidemiol Date: 2016-08-03 Impact factor: 4.897
Authors: Lindsay A Williams; Jun J Yang; Betsy A Hirsch; Erin L Marcotte; Logan G Spector Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-02-15 Impact factor: 4.254
Authors: Jessica L Barrington-Trimis; Myles Cockburn; Catherine Metayer; W James Gauderman; Joseph Wiemels; Roberta McKean-Cowdin Journal: Int J Cancer Date: 2016-11-30 Impact factor: 7.396
Authors: Catherine Metayer; Luoping Zhang; Joseph L Wiemels; Karen Bartley; Joshua Schiffman; Xiaomei Ma; Melinda C Aldrich; Jeffrey S Chang; Steve Selvin; Cecilia H Fu; Jonathan Ducore; Martyn T Smith; Patricia A Buffler Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-07-12 Impact factor: 4.254
Authors: Bonnie R Joubert; Siri E Håberg; Douglas A Bell; Roy M Nilsen; Stein Emil Vollset; Oivind Midttun; Per Magne Ueland; Michael C Wu; Wenche Nystad; Shyamal D Peddada; Stephanie J London Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-04-16 Impact factor: 4.254
Authors: Theodoros N Sergentanis; Thomas P Thomopoulos; Spyros P Gialamas; Maria A Karalexi; Stylianos-Iason Biniaris-Georgallis; Evangelia Kontogeorgi; Paraskevi Papathoma; Gerasimos Tsilimidos; Alkistis Skalkidou; Anastasia N Iliadou; Eleni T Petridou Journal: Eur J Epidemiol Date: 2015-11-04 Impact factor: 8.082